Commentary: The North West London Clinical Trials Alliance: efficiency and innovation in clinical trial delivery

被引:0
|
作者
Kierkegaard, Patrick [1 ,2 ]
Su, Bowen [1 ,2 ]
Wong, Richard [5 ]
Boffito, Marta [3 ,4 ]
Balendra, Suki [3 ]
机构
[1] Imperial Coll London, Canc Res UK Convergence Sci Ctr, London, England
[2] Inst Canc Res, London, England
[3] Imperial Coll Healthcare NHS Trust, London, England
[4] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[5] NIHR Res Delivery Network, London, England
关键词
Clinical trials; Clinical Trials Alliance; COVID-19; Vaccine trials; Digital tools; Participant recruitment; Efficiency; Inclusivity; Equity; Diversity; and Inclusion (EDI); Public health;
D O I
10.1186/s13063-024-08344-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The set-up, activation, and delivery of clinical trials is pivotal for the advancement of medical science, serving as the primary mechanism through which new therapeutic interventions are validated for clinical use. Despite their critical role, the execution of these trials is often encumbered by a multitude of challenges. The North West London Clinical Trials Alliance (The Alliance) was established to address these complexities. It aims to bridge the gap between emerging scientific research and its clinical application through strategic collaborations among healthcare and research entities, thereby enhancing the regional ecosystem for clinical trials. Main text This commentary aims to offer clarity on the fundamental insights that underlie The Alliance, providing a comprehensive understanding of its operational structure and the ecosystem it has fostered to optimise clinical trial delivery and revenue generation. The strategy employed by The Alliance centres on the cultivation of strategic partnerships across a broad spectrum of stakeholders. This approach addresses key operational challenges in clinical trial management, facilitating improvements in the development, setup, activation, and recruitment stages. Notably, The Alliance has reduced the average time to initiate trials to 19 days, compared to the standard 75 days typically observed for commercial setups in North West London. The effectiveness of The Alliance's framework was notably demonstrated during the COVID-19 pandemic, particularly with the expedited recruitment performance in the Janssen COVID-19 vaccine study conducted at Charing Cross Hospital. This instance highlighted the Alliance's capability to meet and exceed recruitment targets promptly while maintaining diversity within study cohorts. Additionally, The Alliance has effectively harnessed digital technology and infrastructure, enhancing its attractiveness to commercially funded studies and illustrating a sustainable model for clinical trial financing and execution. Conclusion The North West London Clinical Trials Alliance represents a strategic response to the conventional challenges faced in clinical trial management, emphasising the importance of cross-sectoral collaboration and resource optimisation. Its efforts, particularly highlighted by its response to the COVID-19 pandemic, provide a case study in enhancing trial delivery and efficiency with significant implications for both regional and global clinical trials research communities.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] APS ACTION - AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
    Erkan, D.
    Lockshin, M. D.
    LUPUS, 2012, 21 (07) : 695 - 698
  • [22] Improving the efficiency of individually randomized clinical trials by staggering the introduction of the intervention
    Hooper, Richard
    Knowles, Charles
    STATISTICS IN MEDICINE, 2019, 38 (01) : 44 - 52
  • [23] Commentary: Indefensible Methods of Handling Missing Data in Clinical Trials
    Arndt, Stephan
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 (12) : 1997 - 1998
  • [24] The community clinical trial system EudraCT at the EMEA for the monitoring of clinical trials in Europe
    H. Krafft
    Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz, 2005, 48 (4): : 453 - 458
  • [25] Harmonizing Quality Improvement Metrics Across Global Trial Networks to Advance Paediatric Clinical Trials Delivery
    Attar, Sabah
    Price, Angie
    Hovinga, Collin
    Stewart, Breanne
    Lacaze-Masmonteil, Thierry
    Bonifazi, Fedele
    Turner, Mark A.
    Fernandes, Ricardo M.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (05) : 953 - 964
  • [26] Barriers to Recruitment and Retention Among Underrepresented Populations in Cancer Clinical Trials: A Qualitative Study of the Perspectives of Clinical Trial Research Coordinating Staff at a Cancer Center
    Yousafi, Sumbul
    Rangachari, Pavani
    Holland, Margaret L.
    JOURNAL OF HEALTHCARE LEADERSHIP, 2024, 16 : 427 - 441
  • [27] A Hybrid Clinical Trial Delivery Model in the COVID-19 Era
    Bhat, Anjana
    Su, Wan-Chun
    Cleffi, Corina
    Srinivasan, Sudha
    PHYSICAL THERAPY, 2021, 101 (08):
  • [28] The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
    Parker, Richard A.
    TRIALS, 2023, 24 (01)
  • [29] The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
    Richard A. Parker
    Trials, 24
  • [30] Cancer clinical trials in Brazil: Limitations and possibilities for health innovation
    Avellar, William de Oliveira
    Antunes, Heliton Spindola
    Ferreira, Edria Aparecida
    Oliveira, Flavia Marilia Fonseca
    Aran, Veronica
    Melo, Andreia Cristina de
    JOURNAL OF CANCER POLICY, 2021, 29